🟢 NEW POSITION $JNCE Target 9.09 for 76.03%🟢 $JNCE Target 12.34 for 76.03%
Or double position at 1.68
Biotech is the shadiest sector to trade, but I love it. Ok, maybe not shady... just volatile.
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.
I finally added my YouTube Training Video to my profile tagline since I’m not allowed to on here. It’s a quick 15 minute training video on how to set up your chart and how to spot opportunities. So check here first but If you have questions just message me.
JNCE
$JNCE TARGET HIT @ 13.76 for 14.76% Profit in 31 daysTARGET HIT @ 13.76 for 14.76% Profit
I took profits today. . . The target was set when I bought it 31 days ago.
GL to those who sell higher…
JNCE: My Next ONTX-like Pick: $6.50 Price TargetFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, here are my insights. JNCE is expected to go up quite soon and is on breakout watch. My recommendation based off of current charting patterns and past wave correlations is to buy now and set a sell order at a $6.50 price target for a similar correlation to ONTX at its bullish runs. I feel like I am actually quite conservative, and am hoping for it to reach around the $7.17 range for its price wall.
JNCE - Huge Buyers Hit Market At Different Trading PriceJounce Therapeutics Inc (NASDAQ: JNCE) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG), the latter of which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY). (Source: finance.yahoo.com)
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
SHORT INTEREST
456.94K 06/28/19
P/E Ratio (with extraordinary items)
-5.04
Analyst Target Price $12.50
Recommendation: HOLD
